| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 7 | 2019 | 788 | 1.170 |
Why?
|
| Pharmacogenetics | 7 | 2019 | 473 | 0.900 |
Why?
|
| Antihypertensive Agents | 4 | 2018 | 273 | 0.800 |
Why?
|
| Cardiovascular Agents | 4 | 2015 | 62 | 0.780 |
Why?
|
| Dyslipidemias | 3 | 2018 | 114 | 0.740 |
Why?
|
| Atrial Fibrillation | 4 | 2014 | 460 | 0.600 |
Why?
|
| Cardiovascular Diseases | 7 | 2015 | 822 | 0.580 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 63 | 0.580 |
Why?
|
| Heart Failure | 6 | 2019 | 1502 | 0.580 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 102 | 0.570 |
Why?
|
| Cardiology | 3 | 2015 | 125 | 0.560 |
Why?
|
| Students, Medical | 1 | 2023 | 449 | 0.530 |
Why?
|
| Coronary Disease | 5 | 2000 | 227 | 0.480 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 3 | 2026 | 278 | 0.470 |
Why?
|
| Physicians | 1 | 2023 | 685 | 0.460 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2005 | 112 | 0.390 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2026 | 406 | 0.390 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 1116 | 0.360 |
Why?
|
| Hemorrhage | 1 | 2014 | 297 | 0.350 |
Why?
|
| Proteinuria | 1 | 2010 | 72 | 0.310 |
Why?
|
| Anticoagulants | 1 | 2014 | 484 | 0.310 |
Why?
|
| Lipids | 1 | 2012 | 295 | 0.310 |
Why?
|
| Myocardial Ischemia | 3 | 2005 | 142 | 0.300 |
Why?
|
| Cerebral Hemorrhage | 2 | 2025 | 377 | 0.290 |
Why?
|
| Humans | 45 | 2026 | 98370 | 0.260 |
Why?
|
| Physician-Patient Relations | 3 | 2023 | 580 | 0.250 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 160 | 0.240 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2010 | 268 | 0.240 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 305 | 0.230 |
Why?
|
| Disease Outbreaks | 1 | 2005 | 149 | 0.210 |
Why?
|
| Metabolic Syndrome | 1 | 2005 | 126 | 0.210 |
Why?
|
| Primary Prevention | 2 | 2000 | 93 | 0.190 |
Why?
|
| Faculty | 1 | 2023 | 40 | 0.190 |
Why?
|
| Point-of-Care Systems | 3 | 2019 | 156 | 0.190 |
Why?
|
| Electric Countershock | 1 | 2003 | 77 | 0.190 |
Why?
|
| Pharmacogenomic Testing | 3 | 2019 | 119 | 0.180 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2012 | 23 | 0.180 |
Why?
|
| Communication | 2 | 2023 | 456 | 0.180 |
Why?
|
| Cardiac Catheterization | 3 | 2012 | 307 | 0.180 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 1993 | 61 | 0.180 |
Why?
|
| Risk Factors | 7 | 2026 | 6273 | 0.170 |
Why?
|
| Thoracic Surgery | 2 | 2012 | 71 | 0.170 |
Why?
|
| Societies, Medical | 2 | 2018 | 687 | 0.170 |
Why?
|
| United States | 9 | 2018 | 8262 | 0.160 |
Why?
|
| Stroke Volume | 2 | 2019 | 464 | 0.160 |
Why?
|
| Hypertriglyceridemia | 1 | 2000 | 71 | 0.160 |
Why?
|
| Hypercholesterolemia | 1 | 2000 | 161 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 64 | 0.150 |
Why?
|
| Physician's Role | 2 | 2017 | 181 | 0.150 |
Why?
|
| Hemangioma, Cavernous | 1 | 2019 | 66 | 0.150 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 132 | 0.140 |
Why?
|
| Diltiazem | 1 | 1998 | 6 | 0.140 |
Why?
|
| Drug Labeling | 2 | 2017 | 44 | 0.140 |
Why?
|
| Treatment Outcome | 8 | 2026 | 9770 | 0.140 |
Why?
|
| Risk | 2 | 2018 | 660 | 0.140 |
Why?
|
| Precision Medicine | 3 | 2019 | 502 | 0.140 |
Why?
|
| Prescription Drugs | 1 | 2019 | 42 | 0.140 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2018 | 25 | 0.140 |
Why?
|
| Sterols | 1 | 2018 | 19 | 0.140 |
Why?
|
| Intestinal Absorption | 1 | 2018 | 125 | 0.130 |
Why?
|
| Dyspnea | 3 | 1996 | 90 | 0.130 |
Why?
|
| Echocardiography | 5 | 2012 | 784 | 0.130 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 73 | 0.130 |
Why?
|
| Female | 20 | 2026 | 51761 | 0.130 |
Why?
|
| Aged | 14 | 2025 | 21844 | 0.130 |
Why?
|
| Male | 18 | 2026 | 47263 | 0.130 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 29 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 1290 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2000 | 402 | 0.120 |
Why?
|
| Tachycardia, Ventricular | 1 | 1998 | 184 | 0.120 |
Why?
|
| Anticholesteremic Agents | 1 | 2018 | 164 | 0.120 |
Why?
|
| Dobutamine | 1 | 1996 | 38 | 0.120 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 1996 | 21 | 0.120 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1996 | 69 | 0.120 |
Why?
|
| Hypotension | 1 | 1996 | 77 | 0.110 |
Why?
|
| Evidence-Based Medicine | 4 | 2005 | 481 | 0.110 |
Why?
|
| Echocardiography, Doppler | 1 | 1996 | 137 | 0.110 |
Why?
|
| Clinical Medicine | 1 | 2015 | 27 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 639 | 0.110 |
Why?
|
| Exercise Test | 1 | 1996 | 158 | 0.110 |
Why?
|
| Intestines | 1 | 2018 | 442 | 0.110 |
Why?
|
| Life Style | 3 | 2000 | 193 | 0.110 |
Why?
|
| Posture | 2 | 1993 | 124 | 0.110 |
Why?
|
| Disease Progression | 1 | 2019 | 1615 | 0.110 |
Why?
|
| Middle Aged | 15 | 2026 | 29532 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 663 | 0.100 |
Why?
|
| Genome, Human | 1 | 2019 | 834 | 0.100 |
Why?
|
| Mitral Valve Prolapse | 1 | 1993 | 18 | 0.100 |
Why?
|
| Program Development | 1 | 2014 | 141 | 0.100 |
Why?
|
| Severity of Illness Index | 4 | 2001 | 2017 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2014 | 202 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 1996 | 540 | 0.090 |
Why?
|
| Blood Proteins | 1 | 1992 | 147 | 0.090 |
Why?
|
| Adult | 9 | 2026 | 29587 | 0.090 |
Why?
|
| Lipoproteins | 1 | 1992 | 136 | 0.090 |
Why?
|
| Counterpulsation | 1 | 1992 | 21 | 0.090 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1992 | 17 | 0.090 |
Why?
|
| Patient Selection | 3 | 2015 | 722 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 1102 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 408 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2014 | 2599 | 0.080 |
Why?
|
| Blood Pressure | 2 | 2010 | 920 | 0.080 |
Why?
|
| Insulin Resistance | 2 | 2005 | 391 | 0.080 |
Why?
|
| General Practitioners | 1 | 2010 | 10 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2025 | 1790 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2026 | 4044 | 0.080 |
Why?
|
| Biomarkers | 2 | 2018 | 2021 | 0.080 |
Why?
|
| Recurrence | 2 | 2026 | 1264 | 0.070 |
Why?
|
| Diabetes Complications | 2 | 2000 | 176 | 0.070 |
Why?
|
| Thrombosis | 1 | 1992 | 318 | 0.070 |
Why?
|
| Diuretics | 2 | 1999 | 78 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 1999 | 99 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 391 | 0.060 |
Why?
|
| Cardiomegaly | 1 | 1988 | 114 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 7418 | 0.060 |
Why?
|
| Models, Biological | 1 | 2014 | 1805 | 0.060 |
Why?
|
| Oxygen | 1 | 1991 | 773 | 0.060 |
Why?
|
| Time Factors | 3 | 2026 | 5577 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 2 | 1999 | 139 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 56 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 602 | 0.060 |
Why?
|
| Algorithms | 1 | 2014 | 2003 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 93 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2019 | 4818 | 0.050 |
Why?
|
| Stroke | 1 | 2014 | 1167 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 1 | 2005 | 170 | 0.050 |
Why?
|
| Heart-Assist Devices | 1 | 1992 | 917 | 0.050 |
Why?
|
| Obesity | 2 | 2000 | 1077 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 418 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 1999 | 396 | 0.050 |
Why?
|
| Diet | 1 | 2005 | 469 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2005 | 1529 | 0.040 |
Why?
|
| Coronary Circulation | 2 | 1992 | 97 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2012 | 152 | 0.040 |
Why?
|
| Coronary Angiography | 2 | 2012 | 238 | 0.040 |
Why?
|
| Contraindications | 1 | 2001 | 66 | 0.040 |
Why?
|
| Microvascular Angina | 1 | 2000 | 1 | 0.040 |
Why?
|
| Niacin | 1 | 2000 | 37 | 0.040 |
Why?
|
| Prognosis | 2 | 2001 | 4126 | 0.040 |
Why?
|
| Morbidity | 1 | 2001 | 163 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2025 | 3612 | 0.040 |
Why?
|
| Guideline Adherence | 2 | 2012 | 250 | 0.040 |
Why?
|
| Physical Examination | 1 | 2001 | 149 | 0.040 |
Why?
|
| Family Practice | 1 | 2000 | 76 | 0.040 |
Why?
|
| Triglycerides | 1 | 2000 | 234 | 0.040 |
Why?
|
| Hypolipidemic Agents | 1 | 2000 | 101 | 0.040 |
Why?
|
| Genotype | 2 | 2015 | 1892 | 0.040 |
Why?
|
| Cause of Death | 1 | 2000 | 278 | 0.040 |
Why?
|
| Administration, Oral | 2 | 1998 | 676 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2019 | 90 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 12 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 765 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 1999 | 118 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2001 | 269 | 0.040 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2001 | 264 | 0.040 |
Why?
|
| Young Adult | 2 | 2025 | 7568 | 0.040 |
Why?
|
| Cholesterol | 1 | 2000 | 376 | 0.040 |
Why?
|
| Chicago | 2 | 2014 | 1519 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 1999 | 101 | 0.030 |
Why?
|
| Proprotein Convertase 9 | 1 | 2018 | 37 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 403 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 169 | 0.030 |
Why?
|
| Research | 1 | 2019 | 257 | 0.030 |
Why?
|
| Digoxin | 1 | 1997 | 21 | 0.030 |
Why?
|
| Exercise | 1 | 2000 | 382 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 1785 | 0.030 |
Why?
|
| Smoking | 1 | 2000 | 676 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 93 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 377 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 1996 | 18 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 257 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1997 | 234 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 1997 | 92 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1996 | 142 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2017 | 217 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 1996 | 179 | 0.030 |
Why?
|
| Sympatholytics | 1 | 1994 | 5 | 0.030 |
Why?
|
| Clonidine | 1 | 1994 | 33 | 0.030 |
Why?
|
| Hospitalization | 1 | 2001 | 988 | 0.030 |
Why?
|
| Anesthesia, Local | 1 | 1994 | 29 | 0.030 |
Why?
|
| Bupivacaine | 1 | 1994 | 48 | 0.030 |
Why?
|
| Incidence | 1 | 1999 | 1787 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1994 | 52 | 0.030 |
Why?
|
| Analgesia | 1 | 1994 | 65 | 0.030 |
Why?
|
| Heart Auscultation | 1 | 1993 | 3 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2018 | 11043 | 0.020 |
Why?
|
| Endocarditis, Bacterial | 1 | 1993 | 38 | 0.020 |
Why?
|
| Anesthesia | 1 | 1994 | 176 | 0.020 |
Why?
|
| Hospitals, University | 1 | 1992 | 192 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 2678 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2012 | 95 | 0.020 |
Why?
|
| Angiography | 1 | 2012 | 194 | 0.020 |
Why?
|
| American Heart Association | 1 | 2012 | 118 | 0.020 |
Why?
|
| Adolescent | 1 | 2025 | 10140 | 0.020 |
Why?
|
| Equipment Failure | 1 | 1992 | 119 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 832 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 1996 | 664 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1991 | 123 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1993 | 237 | 0.020 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1993 | 179 | 0.020 |
Why?
|
| Ventricular Function, Right | 1 | 1991 | 146 | 0.020 |
Why?
|
| Systole | 1 | 2010 | 81 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 3032 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 175 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 3228 | 0.020 |
Why?
|
| Awareness | 1 | 2010 | 93 | 0.020 |
Why?
|
| Prevalence | 1 | 1993 | 1393 | 0.020 |
Why?
|
| Comorbidity | 1 | 1992 | 1035 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1992 | 746 | 0.020 |
Why?
|
| Age Factors | 1 | 1992 | 1974 | 0.020 |
Why?
|
| Hypoxia | 1 | 1993 | 682 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 419 | 0.020 |
Why?
|
| Intermittent Claudication | 1 | 2005 | 20 | 0.010 |
Why?
|
| Nutrition Policy | 1 | 2005 | 13 | 0.010 |
Why?
|
| Aneurysm | 1 | 2005 | 58 | 0.010 |
Why?
|
| Premedication | 2 | 1994 | 57 | 0.010 |
Why?
|
| Extremities | 1 | 2005 | 173 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1010 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1276 | 0.010 |
Why?
|
| Length of Stay | 1 | 2005 | 876 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2001 | 36 | 0.010 |
Why?
|
| Ventricular Dysfunction | 1 | 2001 | 24 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 2050 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 992 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2001 | 103 | 0.010 |
Why?
|
| Enflurane | 1 | 1994 | 2 | 0.010 |
Why?
|
| Sufentanil | 1 | 1994 | 3 | 0.010 |
Why?
|
| Receptors, Adrenergic | 1 | 1994 | 14 | 0.010 |
Why?
|
| Diazepam | 1 | 1994 | 26 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 1994 | 66 | 0.010 |
Why?
|
| Epinephrine | 1 | 1994 | 91 | 0.010 |
Why?
|
| Placebos | 1 | 1994 | 210 | 0.010 |
Why?
|
| Urodynamics | 1 | 1994 | 130 | 0.010 |
Why?
|
| Nitrous Oxide | 1 | 1994 | 108 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 2688 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1994 | 237 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 837 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1994 | 305 | 0.010 |
Why?
|
| Respiration | 1 | 1994 | 272 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1994 | 255 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1994 | 224 | 0.010 |
Why?
|
| Heart Rate | 1 | 1994 | 534 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1994 | 528 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1994 | 914 | 0.000 |
Why?
|